Article: InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe

Article - Media, Publications

InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe

PRNewswire, 19 January 2021

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), today announced that executives of the Company will speak at the 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe (“CDP Europe”). CDP Europe will be held virtually from January 19-21, 2021. Michael Woudenberg – Vice President, Chemistry, Manufacturing & Controls, Karen Long – Senior Director, Drug Development, and Prof. Mauro Maccarrone PhD – Scientific Advisor to InMed will all be featured as expert speakers at the event.

Read Full Article

Article: InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family

Uncategorized

InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family

PRNewswire, 19 May 2020

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today announced the filing of a key Patent Cooperation Treaty (“PCT”) patent application directed to the Company’s biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids.

The PCT patent application entitled “Compositions and Methods for Biosynthesis of Terpenoids or Cannabinoids in a Heterologous System” was initially filed as two separate United States Provisional Patent applications and further addresses the enablement and maximization of cannabinoid production through optimization of the precursor substrates needed to support specific cannabinoid synthesis.

Read Full Article

THE DOLLAR HAS NO INTRINSIC VALUE : DO YOUR ASSETS?